Insider Selling: Billiontoone (NASDAQ:BLLN) Insider Sells $100,052.91 in Stock

Billiontoone, Inc. (NASDAQ:BLLN) insider Nancy Joann Johnson sold 801 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $124.91, for a total transaction of $100,052.91. Following the sale, the insider directly owned 21,099 shares of the company’s stock, valued at approximately $2,635,476.09. This represents a 3.66% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Nancy Joann Johnson also recently made the following trade(s):

• On Tuesday, June 9th, Nancy Joann Johnson sold 10,582 shares of Billiontoone stock. The stock was sold at an average price of $100.47, for a total transaction of $1,063,173.54.
• On Monday, June 8th, Nancy Joann Johnson sold 3,418 shares of Billiontoone stock. The shares were sold at an average price of $99.28, for a total value of $339,339.04.

Billiontoone Stock Up 2.2%

NASDAQ:BLLN opened at $120.60 on Thursday. The company has a current ratio of 10.92, a quick ratio of 10.58 and a debt-to-equity ratio of 0.18. The stock has a 50 day moving average of $98.44 and a 200-day moving average of $88.44. The firm has a market capitalization of $5.55 billion and a PE ratio of 219.27. Billiontoone, Inc. has a 52 week low of $61.96 and a 52 week high of $138.70.

Billiontoone (NASDAQ:BLLN) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.33. The company had revenue of $108.39 million during the quarter, compared to the consensus estimate of $95.81 million. During the same period last year, the business posted ($0.39) EPS. The company’s revenue for the quarter was up 83.8% on a year-over-year basis. Analysts predict that Billiontoone, Inc. will post 0.93 EPS for the current year.

Institutional Investors Weigh In On Billiontoone

Several institutional investors have recently bought and sold shares of the stock. Green Alpha Advisors LLC acquired a new position in Billiontoone during the 4th quarter valued at about $436,000. FNY Investment Advisers LLC acquired a new stake in shares of Billiontoone in the 4th quarter worth approximately $497,000. Massachusetts Financial Services Co. MA bought a new position in shares of Billiontoone in the fourth quarter valued at approximately $13,373,000. Baillie Gifford & Co. bought a new position in shares of Billiontoone in the fourth quarter valued at approximately $103,786,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Billiontoone during the fourth quarter valued at approximately $1,348,000.

Analysts Set New Price Targets

Several equities analysts have recently commented on BLLN shares. Weiss Ratings upgraded shares of Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd. Guggenheim initiated coverage on shares of Billiontoone in a research note on Monday, June 29th. They issued a “buy” rating and a $125.00 price target on the stock. BTIG Research cut their price target on Billiontoone from $140.00 to $130.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Finally, JPMorgan Chase & Co. increased their price objective on Billiontoone from $120.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Six research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Billiontoone presently has a consensus rating of “Moderate Buy” and a consensus target price of $126.00.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.